- Trials with a EudraCT protocol (1,111)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,111 result(s) found for: Brain function.
Displaying page 9 of 56.
EudraCT Number: 2016-003343-11 | Sponsor Protocol Number: GLP1ALCOHOL | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Psychiatric Centre Copenhagen | |||||||||||||
Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence? | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001252-35 | Sponsor Protocol Number: DANA-2018-1. | Start Date*: 2018-09-06 |
Sponsor Name:Kirsten Møller | ||
Full Title: Neuroplasticity induced by general anaesthesia | ||
Medical condition: This trial investigates the effects of general anaesthesia on the helathy human brain. Thus, only healthy, young adults with no medical conditions will participate as volunteers in this study. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-003742-36 | Sponsor Protocol Number: MK-3475-02D | Start Date*: 2021-02-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001755-45 | Sponsor Protocol Number: OX4325 | Start Date*: 2016-09-12 | |||||||||||||||||||||
Sponsor Name:Mateon Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bev... | |||||||||||||||||||||||
Medical condition: Platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014909-14 | Sponsor Protocol Number: CS/München01 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Max-Planck-Institut für Psychiatrie | |||||||||||||
Full Title: Neuropsychological effects of hydrocortisone substitution in patients with partial adrenal insufficiency after traumatic brain injury or subarachnoidal haemorrhage | |||||||||||||
Medical condition: hormonal deficiency after traumatic-brain- injury (TBI) or subarachnoidal haemorrhage (SAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001642-14 | Sponsor Protocol Number: n/a | Start Date*: 2011-07-11 |
Sponsor Name:University of Surrey | ||
Full Title: The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes | ||
Medical condition: Type 1 diabetes mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-018153-23 | Sponsor Protocol Number: | Start Date*: 2010-09-30 |
Sponsor Name:University of Oxford | ||
Full Title: A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma | ||
Medical condition: Advanced metastatic melanoma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002070-23 | Sponsor Protocol Number: EEGrofl | Start Date*: 2011-10-12 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: Effects of roflumilast on cognition in healthy adults: a behaviour-EEG study | ||
Medical condition: None; this proof-of-principle study will examine the cognition enhancing effects of roflumilast in healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000287-17 | Sponsor Protocol Number: RC12-01 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
Full Title: PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI | |||||||||||||
Medical condition: Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022598-32 | Sponsor Protocol Number: ABE4955g | Start Date*: 2011-07-13 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE IMPACT OF MABT5102A ON BRAIN AMYLOID LOAD AND RELATED BIOMARKERS IN PATIENTS WITH MILD TO... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003586-41 | Sponsor Protocol Number: A6281289 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | |||||||||||||
Full Title: Placebo-controlled trial on the efficacy of growth hormone replacement therapy in patients with growth hormone deficiency after traumatic brain injury | |||||||||||||
Medical condition: Growth hormone deficiency after traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005143-28 | Sponsor Protocol Number: MED.RES.HOS.2006.03.LP | Start Date*: 2006-12-06 |
Sponsor Name:Medicinsk Forskning | ||
Full Title: Effects of HMG-CoA-reductase inhibition (atorvastatin) on renal sodium excretion, renal hemodynamics, tubular function and vasoactive hormones in healthy subjects under diet with normal and high so... | ||
Medical condition: Healthy volunteer trial | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003284-19 | Sponsor Protocol Number: CTU/2013/073 | Start Date*: 2017-01-24 |
Sponsor Name:University College London | ||
Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease. | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002689-30 | Sponsor Protocol Number: MedOPP107 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MedSIR ARO) | |||||||||||||
Full Title: Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer | |||||||||||||
Medical condition: Progressing brain metastases in patients with HER2-negative breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003127-38 | Sponsor Protocol Number: NL71001.029.19 | Start Date*: 2020-04-09 |
Sponsor Name:VUmc Neurology Department | ||
Full Title: Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial. | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001799-12 | Sponsor Protocol Number: EVER-AT-0618 | Start Date*: 2019-09-18 | |||||||||||
Sponsor Name:EVER Neuro Pharma GmbH | |||||||||||||
Full Title: IMPULSE StIMulation of brain Plasticity to improve Upper Limb recovery after StrokE A prospective, multi-center, randomized, double-blind study to assess efficacy and safety of neuroplastic interv... | |||||||||||||
Medical condition: Subacute and chronic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004685-10 | Sponsor Protocol Number: PD-1105 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Voyager Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuatio... | |||||||||||||
Medical condition: Patients with Parkinson's Disease with motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004474-15 | Sponsor Protocol Number: PETFLUTEMETAMOL-FDG/BBRC2015 | Start Date*: 2016-03-14 | ||||||||||||||||
Sponsor Name:BarcelonaBeta Brain Research Center | ||||||||||||||||||
Full Title: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project | ||||||||||||||||||
Medical condition: Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001671-30 | Sponsor Protocol Number: 2013-TL-MEL-Th | Start Date*: 2015-07-31 | |||||||||||
Sponsor Name:Centre Eugène Marquis | |||||||||||||
Full Title: Evaluation of cobimetinib + vemurafenib combination treatment in patients with brain metastasis BRAFV600 mutated cutaneous melanoma | |||||||||||||
Medical condition: Patients with brain metastasis (BM) from BRAFV600-mutated cutaneous melanoma. Patients will be enrolled into three cohorts: A. Neurologically asymptomatic patients who have not received prior loc... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002903-25 | Sponsor Protocol Number: CC-4047-BRN-001 | Start Date*: 2017-07-19 |
Sponsor Name:Celgene Corporation | ||
Full Title: A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. | ||
Medical condition: Recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
